Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2025)

Cytek Biosciences' Accumulated Expenses history spans 6 years, with the latest figure at $23.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 9.21% year-over-year to $23.4 million; the TTM value through Dec 2025 reached $23.4 million, up 9.21%, while the annual FY2025 figure was $23.4 million, 9.21% up from the prior year.
  • Accumulated Expenses reached $23.4 million in Q4 2025 per CTKB's latest filing, up from $20.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.4 million in Q4 2025 to a low of $10.8 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $18.3 million, with a median of $19.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: soared 68.56% in 2021, then fell 20.94% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $15.3 million in 2021, then skyrocketed by 38.52% to $21.1 million in 2022, then fell by 5.16% to $20.0 million in 2023, then grew by 7.03% to $21.4 million in 2024, then rose by 9.21% to $23.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Accumulated Expenses are $23.4 million (Q4 2025), $20.2 million (Q3 2025), and $21.6 million (Q2 2025).